Delic Labs Applies for Dealers License to Commercialize Psychedelics Research, Health Exemption to Test MDMA and LSD

DELIC LABS APPLIES FOR DEALER’S LICENSE TO COMMERCIALIZE PSYCHEDELICS RESEARCH, HEALTH EXEMPTION TO TEST MDMA AND LSD

License Allows Authority to Work with Additional Banned Substances and Market the Research for Medical Purposes

Vancouver, British Columbia – October 6, 2021 – Delic Holding Corp Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), the leading psychedelic wellness platform, today announced Delic Labs has applied for a Health Canada 56 Research Exemption that would allow the scientists to perform research and tests on a host of compounds outside of psychedelic mushrooms, including MDMA and LSD. The lab currently holds a 56 Research Exemption for chemistry analytics on psilocybin mushrooms.

Additionally, the lab has applied for a Dealer’s License and intends to eventually commercialize its psilocybin research and associated intellectual property (IP) for medical and research purposes. Some of the work would include researching extraction of pharmaceutically relevant compounds from psychedelic mushrooms and turning those extracts into medical products. Additionally, Delic Labs will synthesize non-naturally occurring compounds as part of its ongoing med-chem pipeline..

Delic Labs is a federally-authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development. Delic Labs serves as the engine for the Delic platform, conducting research and developing innovative product lines and intellectual property, including psilocybin vaporization technology for future distribution across the Company’s physical footprint and licensed psychedelic wellness clinics in the United States.

Matt Stang, co-founder and CEO of Delic Corp, stated, “Never before has a lab been authorized to test psychedelic compounds such as MDMA and LSD with the opportunity to create new medicines for the millions suffering from debilitating conditions like depression, anxiety, PTSD and Parkinson’s disease. Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced using them, while also actively researching potential new medicines for the market.”

Dr. Markus Roggen, co-founder of DELIC Labs stated, “Once we secure this 56 Research Exemption together with the Dealer’s License, Delic Labs will become the leader in safety testing of psychedelic compounds to ensure the highest standards and quality control. We will greatly expand our capabilities to work with other banned substances, such as MDMA and LSD, along with psilocybin to develop new psychedelic drugs for medical and research purposes. We believe we are on the cusp of understanding the breadth of what is possible with psychedelics and medicine.”

Founded by Dr. Roggen, an award-winning chemist, and UBC Professor, Dr. Glenn Sammis, Delic Labs supports the psychedelic industry with high precision chemical analytics, metabolomic identification and process optimization. Delic Labs is one of a handful of licensed psilocybin research labs in Canada and has an aggressive plan to build out a suite of novel compounds and delivery methods for the industry. Delic Labs is also a leading cannabis analytical and research company boasting clients that include some of the largest brands in the world.

About Delic Labs (formerly Complex Biotech Discovery Ventures Ltd.)

Delic Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, Delic Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the Delic Corp family, the leading psychedelic wellness platform, Delic Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.

About DELIC Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed [6] entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

Media and Investor Relations Contact

Rich Rodriguez

rich@deliccorp.com

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to:

assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

October 5, 2021March 10, 2022

Dr. Molly Maloof, Physician, Technologist and Entrepreneur, To Keynote At Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Meet Delic, the revolutionary, two-day immersive edutainment experience for the world’s leading psychedelic and wellness thought and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, October 5, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness platform, today announced that Dr. Molly Maloof, MD, will serve as a keynote speaker at Meet Delic on November 6. Dr. Maloof has worked with investors, entrepreneurs, and executives to optimize their health and consulted with more than 45 companies in the digital health, consumer health, and biotechnology industries needing help with clinical strategy, product development, clinical research and scientific marketing. She is also the co-founder of the Psychedelic Clubhouse on the Clubhouse app where she co-hosts the Psychedelic News Hour.

Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, wellness, and business with like-minded visionaries. Dr. Maloof’s keynote, Aphrodisiacs and Psychedelics: A History of Medicine for Love, will explore psychedelic aphrodisiacs and provide historical, modern day and future contexts for the role of psychedelics in human relationships.

“I’m super excited to speak at Meet Delic, the premier consumer psychedelic conference,” said Maloof. “They are truly making history by bringing people together in Las Vegas during a time when we need community and connection more than ever. I couldn’t be more honored to speak at such an important conference in such a pivotal point in history. It’s going to be a blast.”

Meet Delic is committed to bringing awareness of the science-backed benefits of psychedelics and business opportunities to the mainstream and larger global community by reframing the psychedelic conversation. The experiential event will feature dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations and one of the world’s largest psychedelic business expo.

“Molly has deep experience in the space where health, wellness, technology and business intersect,” said Delic co-founder, Jackee Stang. “Her entrepreneurial spirit drives her to create new channels for people to learn about optimizing their health and wellness, and we are happy to have Molly speak at Meet Delic.”

The twenty hours of panels and keynotes will include an array of topics such as Psychedelics and the Search for Truth, Why Are Psychedelics Medicine?, The Shortcomings of Wellness, PTSD Reset and Recovery, Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World, Psychedelics and Sobriety: The Next Frontier in Recovery, Microdosing, Psychedelic Activism, Digital Dosing: Technology & Innovation Powering Psychedelics, How Psychedelics Can be Effectively Used for Physical Optimization, and Drug Use for Grown-Ups. Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of

this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

October 5, 2021March 10, 2022

Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application

Company utilizes green chemistry to stabilize natural product with higher yields

VANCOUVER, BC (October 5, 2021) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to advise of a recent patent filing pertaining to a breakthrough process that facilitates the extraction of the natural products Psilocybin and Psilocin from mushrooms at higher yields than previously possible.

The instability of Psilocybin and Psilocin has historically been a difficult problem to solve. Compared to the total alkaloid content believed to be in mushrooms, analytical chemistry studies have shown a 3-fold decrease in the total alkaloid content when the alkaloids are extracted from mushrooms that have been subjected to dehydration. Optimi has discovered a novel, high yielding extraction technique by combining multiple process steps that collectively increase the total yield of alkaloids retrieved from the mushrooms.

Many companies in the sector frequently use synthetic Psilocybin due to the instability of Psilocin which has been shown to degrade due to its phenolic hydroxy group. Optimi’s unique extraction technique not only increases overall alkaloid yield, but also protects the active alkaloids from degradation. Optimi Health Chief Scientific Officer, Justin Kirkland notes, “I find the compounds produced by these mushrooms as quite precious and am delighted to have developed a procedure that maintains their integrity.”

This innovative molecular protection process is believed to increase the bioavailability and permeability of the active components of the mushroom. In keeping with Optimi Health’s commitment to sustainability and the environment, the proprietary process protected in the patent filing extensively utilizes green chemistry. Additionally, the process aids in lowering the cost of the final drug product for the patient as well as creating improved manufacturing efficiencies and improved safety characteristics related to farm operations.

Optimi Health CEO Bill Ciprick states, “Today’s announcement reflects our determination to advance the innovation of all-natural mushroom science. We’ve achieved a singular achievement which will ultimately enable future patients the ability to select a superior, natural solution for their needs. The fact our process is both cost-effective and offers higher yields is, of course, a potentially significant commercial factor for us. We are looking forward to implementing these improved procedures as the construction of our mushroom farm facilities nears completion and are excited to continue to develop our inhouse IP portfolio to bring added value to our venture and ultimately to our shareholders.”

On Behalf of the Board of Directors,

Bill Ciprick
Chief Executive Officer
Optimi Health Corp.

ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the Company’s potential Nasdaq listing, the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

October 1, 2021March 15, 2022

Wesana Health Announces Inclusion in the AdvisorShares Psychedelics ETF

CHICAGO and TORONTO, Oct. 01, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, is pleased to announce its inclusion in the AdvisorShares Psychedelics ETF (the “Fund”), currently trading under the ticker symbol “PSIL” on the NYSE Arca exchange.

The recently launched Fund primarily focuses its strategy on investing in publicly traded companies in the life sciences, biotechnology and pharmaceuticals sectors that derive at least 50% of their net revenue or devote 50% of their assets to the advancement of psychedelic compounds. The Fund looks to highlight the leaders in the psychedelics sector as their core holdings.

Chad Bronstein, Executive Chairman of Wesana, commented: “We are incredibly pleased to have been selected as a core constituent in the new AdvisorShares Psychedelics ETF. Inclusion in this ETF is another validation in the evolution of Wesana as a publicly traded company and the impact Wesana’s core initiatives have had on the psychedelics sector. By strengthening our shareholder base and improving our visibility in the global investment community, we are excited for the next steps in bringing Wesana’s unique approach to neurological health and wellness to patients across the country.”

You can find additional information on the AdvisorShares Psychedelics ETF here.

About Wesana Health
Wesana Health is an emerging life sciences company championing the development of innovative approaches for better understanding, protecting and improving neurological health and performance. Through extensive clinical research and academic partnerships, Wesana Health is developing evidence-based formulations and protocols, including psilocybin-based therapies, that empower patients to overcome neurological, psychological and mental health ailments. Learn more at www.wesanahealth.com.

Forward-Looking Information and Statements

This press release contains “forward-looking information” within the meaning of applicable securities laws with respect to the Company, including, but not limited to: information concerning completion and timing of completion of the issuance of DRS statements to the former PsyTech shareholders, expectations for the effects of the proposed Transaction, including the potential expansion of the clinic platform of the Company upon completion of the Transaction, expectations regarding the markets to be entered into by the Company as a result of completing the Transaction, the ability of the Company to successfully achieve its business objectives as a result of completing the Transaction, expectations regarding the method by which future revenue is generated, and any other statement that may predict, forecast, indicate or imply future plans, intentions, levels of activity, results, financial position, operational or financial performance or achievements. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, will”, “projects”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about: development costs remaining consistent with budgets; favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labor stability; stability in capital goods markets; the level of demand for the Company’s products and services; the ability of the Company to be successful in its research and development initiatives; and the availability of third party service providers and other inputs for the Company’s operations. While the Company considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of the Company and there is no assurance they will prove to be correct.

Furthermore, such forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, financial position, performance or achievements of the Company to be materially different from any future plans, intentions, activities, results, financial position, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: research and development of drugs targeting the central nervous system (“CNS”) being particularly difficult; failure to comply with health and data protection laws and regulations; delays in clinical testing resulting in delays in commercializing; inability to file investigational new drug applications to commence clinical trials in a timely manner; difficulty enrolling patients in clinical trials; competition from other biotechnology and pharmaceutical companies; violations of laws and regulations resulting in repercussions; psychedelic inspired drugs possibly never being approved as medicines; regulatory or political change; maintaining and enhancing reputation and brand recognition; reliance on third parties to plan, conduct and monitor preclinical studies and clinical trials; requirements of commercial scale and quality manufactured drug supply; negative results from clinical trials or studies of others; negative operating cash flow and going concern; the detrimental impact of future losses and negative cash flow from operations; requirements for additional capital; lack of product revenue; unfavourable publicity or consumer perception; not achieving publicly announced milestones; reliance on the capabilities and experience of key executives and scientists; disruptions due to acquisitions or collaborations; risk of product liability claims; COVID-19; litigation; conflicts of interest; limited operating history; exposure to the fluctuation of foreign exchange rates; enforcement of judgments and effecting service of process on directors and officers; ability to protect intellectual property; changes in patent law; requirements to share intellectual property with service providers; general economic, market and business conditions, other risks factors including those found in the Company’s annual information form dated September 3, 2021 filed on the Company’s profile on SEDAR at www.sedar.com and discussed in the Company’s other public filings available on SEDAR. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is provided and made as of the date of this news release and the Company does not undertake any obligation to revise or update any forward-looking information other than as required by applicable law.

For more information, please contact:

Investor Contact:
Keenan Gentry
Email: IR@wesanahealth.com
Phone: 773-236-7972

Media Contacts:
Nick Opich / Fallon Carter
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer
Phone: (773) 236-7972

Source: Wesana Health

Released October 1, 2021

September 30, 2021March 10, 2022

Delic Partnership With Paradigm Healthcare Of Georgia Brings Clinically Relevant Toxicology Testing To Ketamine Treatment For First Time

Psychedelic Treatment Chain Ketamine Infusion Centers Will Leverage State-of-the-Art Toxicology Testing Solution to Ensure Highest Quality Results Across Locations

Vancouver, British Columbia – September 30, 2021 – Delic Holding Corp Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness platform, today announced a first of its kind partnership with Paradigm Healthcare, an independent clinical laboratory located in St. Simons, Georgia, United States, with a focus on high complexity, clinical toxicology, to bring state-of-the-art testing to Ketamine Infusion Centers LLC (“KIC”). Through the partnership, KIC will have access to Paradigm’s Benchmark UDT™ toxicology solution that uses LC/MS/MS test methods to identify and accurately measure drug compounds in the body, ensuring the highest quality toxicology results and clinically relevant test data to support medical decision-making.

The addition of Paradigm’s innovative Benchmark UDT™ test platform gives KIC the ability to:

Identify any type of drug that may already be present in a patient’s system to avoid potential conflicts with ketamine infusion and to ensure patient safety before ketamine treatment is started.
Detect very high levels of ketamine and norketamine, thereby enabling KIC clinicians to make patient-specific treatment decisions and to ensure proper ketamine levels are maintained throughout infusion treatment.
Compare ketamine and norketamine levels with analytical data captured from Clinifusion EMR, including benchmarks when treatment started and ended, at what point patients began getting better, and the number of times the patient visited the clinics for treatments, to provide the best overview of a patient’s treatment journey.

Matt Stang, founder and CEO of DELIC stated, “Paradigm’s Benchmark testing platform brings state-of-the-art drug testing technology and new reporting tools to clinicians who use psychedelics to treat people with serious behavioral health conditions; We are proud to partner with Paradigm. By integrating their state-of-the-art testing capabilities, KIC will be able to provide patients suffering from depression, anxiety, PTSD and other debilitating conditions the most accurate, personalized ketamine treatment protocol in the industry.”

“We believe this partnership with Paradigm will take patient care to the next level,” said Sonny Diaz, co-founder of KIC. “Their powerful toxicology testing gives us the ability to quickly assess a patient’s system ahead of treatment and develop a custom plan for moving them through the protocol. Paired with data from Clinifusion EMR, we can see exactly when they started to get better and can keep people at the right levels to maintain their wellness. KIC will be the only clinic able to aggregate this type of analytical data and validate the results.”

Catherine Veal, President, Paradigm stated, “We are very excited about this partnership with Delic and KIC. Paradigm is committed to providing the best scientific data available to support KIC and Delic in their efforts to combine laboratory science with the developing science of psychedelic treatments in patient care. Our industry-leading toxicology testing will now be available to help people who struggle with different behavioral health conditions, including PTSD, major depression, anxiety, as they undergo ketamine infusion to find their way back to better health and wellness.”

KIC enables Delic to leverage its central hub of psychedelic education, media, and information sources to patients seeking psychedelic therapy. Delic Corp is uniquely positioned to bring digital awareness to its various holdings under the Delic Corp umbrella, and drive online users to brick and mortar holdings, including KIC’s physical psychedelic clinics.

Over the last 3 years, KIC has expanded from Arizona to California, while overseeing 4,000 treatments delivered to date, and generating over USD$1.5MM in revenue. KIC operates under the Delic Corp umbrella, under the direction and guidance of Diaz, Dr. Christopher Ray, Rogelio Monzon, and Ganesh Acharya.

About Paradigm Healthcare

Paradigm is based in the United States and its laboratory is located in St. Simons, Georgia. Paradigm is accredited through the College of American Pathologists (CAP) and CLIA. Paradigm performs high-complexity toxicology testing. Paradigm’s laboratory personnel are very experienced and understand the challenges clinicians face when using laboratory science to support quality patient care. For more information about Paradigm and its Benchmark UDT™ testing platform and support of KIC, contact Ananda Smith, Sales Director at +1 (602) 689-9102 or anandas@paradigm.healthcare. Paradigm is not affiliated with Paradigm Labs of Arizona.

About Ketamine Infusion Centers

Ketamine Infusion Centers (“KIC”) is the leading ketamine infusion treatment clinic chain and one of the most experienced in the country, operating locations in California and Arizona. KIC’s evidence-based practices, peer-reviewed studies, and superior quality products result in the best standard of care for legal psychedelic treatments to combat chronic diseases and pain disorders. Part of the Delic Corp family, the leading psychedelic wellness platform, KIC is committed to expanding greater treatment access for patients and improving patient outcomes.

About DELIC Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed [6] entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.9

Media and Investor Relations Contact

Rich Rodriguez

rich@deliccorp.com

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

September 29, 2021March 10, 2022

Red Light Holland: Initial Results From Red Light Oregon Market Research in Oregon Show 86% of Adults Interested in Psilocybin Services are Interested in Microdosing

Toronto, Ontario–(Newsfile Corp. – September 29, 2021) – Red Light Oregon, Inc. (“Red Light Oregon“) a 50/50 joint venture of Halo Collective Inc. (NEO: HALO) (OTCQB: HCANF) (FSE: A9K) (“Halo Collective“) and Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF), (“Red Light Holland“), is pleased to announce preliminary findings from a statistically significant and representative market study of Oregon adults. The market research study (the “Market Research Study“), aimed to gather insights on the likely beneficiaries of Measure 109 and the legalization of psilocybin services by the Oregon Health Authority (“Psilocybin Services“) for adults in Oregon and help support the Oregon Psilocybin Advisory Board (OPAB) and health officials in making data-informed regulations.

The market research utilized an online survey with 13 questions answered by 473 Oregonians. The survey was powered by Dynata Insights Platform to ensure accurate quota sampling. The data was analyzed by data scientist Alicia Chen.

Some Initial data from the Market Research Study has uncovered:

● 86% of adults interested in Psilocybin Services are interested in microdosing.
● 49% of those interested in Psilocybin Services are interested in services such as increasing creativity (35%), exploring their mind (29%) and exploring spirituality (29%).
● Oregonians who are not interested in Psilocybin Services because they don’t want to pay for them list their largest concern is supporting Big Pharma.
● 84% of those interested in Psilocybin Services are interested in services to help with their mental health.
● While nearly half of all adults (49%) are interested in paying for Psilocybin Services, 37% of Adults in Oregon do not know what psilocybin is. In addition, women, people who have not completed a college degree, and Asian minorities in Oregon are less likely to know what psilocybin is.
● On average, people would like to pay around $100 USD for a psilocybin therapy session and approximately $50 USD for a microdosing session. However, there is a significant difference between those in lower-income brackets vs. higher income brackets ($93 USD vs. $223 USD, respectively).
● There is a trend showing younger adults are more interested in Microdosing than Boomers (94% Gen Z, 74% Boomers), although it did not reach statistical significance in the sample size.

Based on this data, Red Light Oregon has:

● Launched a community outreach program to educate the public and health care providers about the latest scientific research around psilocybin and the opportunities of Measure 109. Red Light Oregon will be focusing on reaching out to underserved populations, as seen in the data, which have not had the privilege to be exposed to the potential benefits of psilocybin. The program will utilize Wisdom, a VR app that explains the effects of psilocybin on the brain. You can register to receive more information on: https://redlightoregon.com/.
● Launched an advocacy program to educate the Oregon Psilocybin Advisory Board and Oregon health officials around the potential benefits of microdosing and the ability to increase the equity of Measure 109 with regulation specifically addressing microdosing, which is a lower-priced service. Red Light Oregon aims to work with Oregon authorities utilizing Red Light Oregon’s legal advisor to assist in bridging the gap between regulations and what the people in Oregon want.

Below are some of the answers from the 49% of adults in the sample from Oregon interested in paying for Psilocybin Services.

Figure 1

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_001full.jpg

Figure 2

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_002full.jpg

Figure 3

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_003full.jpg

Figure 4

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_004full.jpg

“The data Red Light Oregon has received, so far, from Oregon is showing the immediate need people have for psychedelic services to help with mental health. The data also shows many of them are interested in microdosing,” said Todd Shapiro, CEO, and Director of Red Light Holland. “Measure 109 is focused on equity, and equity starts with education, which is why we have launched our community outreach program. Oregonians have also shown us their genuine concern around supporting Big Pharma and Red Light Oregon is committed to being the people’s company starting by listening to what the people want while advocating for legal access through education, information, and responsible use.”

“With 51% of adults interested in Psilocybin Services and 88% of those respondents being interested in microdosing, we believe there is a huge opportunity for a company with our shared expertise to provide the people of Oregon with the best services,” added Katie Field, Co-President of Red Light Oregon and President and Executive Director at Halo Collective.

“Psilocybin has meaningful potential to help people grow and heal, and it’s everyone’s responsibility to make sure the benefits from this natural substance are available to everyone even if they don’t make six figures. We are impressed with the OPAB’s emphasis on equity and hope this data will help them come up with recommendations that will ensure this goal. For Measure 109 to be equitable, it should also take into account the wants of the younger generation and make sure that group sessions and microdosing are clearly defined in the regulation to increase accessibility to lower-priced Psilocybin Services,” said Sarah Hashkes, Co-president of Red Light Oregon and Chief Technology and Innovation Officer of Red Light Holland.

Further data from the survey continues to be analyzed. An official report is estimated to be released to the public, the OPAB and health officials in mid-October.

Measure 109 will make Psilocybin Services available to 21 years and older in Oregon who think they can benefit from them without a need for medical diagnosis. The service must include a required prep-session, psilocybin session in a licensed facility supervised by a licensed facilitator and a possibility of an integration session. On December 31, 2022, the Oregon Health Authority will prescribe forms and regulations necessary for the exact implementation.

About Red Light Oregon

Red Light Oregon is an Oregon-based company that is a 50/50 joint venture between Halo Collective Inc. and Red Light Holland Corp. Red Light Oregon is developing a commercialization strategy for Psilocybin Services in Oregon utilizing a holistic approach based on the latest neuroscience research and in accordance with Measure 109, which is a measure aimed at legalizing Psilocybin Services. In addition, Red Light Oregon focuses on increasing accessibility and equity to Psilocybin Services in Oregon by promoting education, research, and accessible pricing.

About Halo Collective Inc.

Halo Collective is a leading, vertically integrated cannabis company that cultivates, extracts, manufactures, and distributes quality cannabis flower, oils, and concentrates and has sold approximately eleven million grams of oils and concentrates since inception. The company continues to expand its business and scale efficiently, partnering with trustworthy leaders in the industry who value Halo Collective’s operational expertise in bringing top-tier products to market.

Halo Collective currently operates in the United States in Oregon and California, Canada, Southern Africa in the Kingdom of Lesotho, and the United Kingdom. The company sells cannabis products principally to dispensaries in the U.S. under its brands Hush, Mojave, and Exhale, and under license agreements with Papa’s Herb®, DNA Genetics, Terphogz, and FlowerShop*, a cannabis lifestyle and conceptual wellness brand that includes G-Eazy as a partner and key member.

As part of continued expansion and vertical integration in the U.S., Halo Collective boasts several grow operations throughout Oregon and two planned in California. In Oregon, the company has a combined 11 acres of owned and contracted outdoor and greenhouse cultivation, including East Evans Creek, a six-acre grow site in Jackson County with four licenses owned and operated by Halo Collective and two third-party licenses under contract to sell all of their product to Halo Collective; Winberry Farms, a one-acre grow site located 30 miles outside of Eugene in Lane County with a license owned and operated by Halo Collective; and William’s Wonder Farms, a three-acre grow site in Applegate Valley, under contract to sell all of its product to Halo Collective pending the closing of Halo Collective’s acquisition of its licenses and business assets. Halo Collective has recently acquired Food Concepts LLC, a master tenant of a 55,000 sq.ft. indoor cannabis cultivation, processing, and wholesaling facility in Portland, Oregon operated by the Pistil Point entities.

In California, the company is building out Ukiah Ventures, a planned 30,000 sq. ft. indoor cannabis grow and processing facility, which will include up to an additional five acres of industrial land to expand the site. Recently, Halo Collective partnered with Green Matter Holding in California to purchase a property in Lake County, developing up to 63 acres of cultivation, comprising one of the largest licensed single site grows in California. Halo Collective also plans to expand its operations in California by opening three dispensaries in North Hollywood, Hollywood, and Westwood, one of which may serve as the first FlowerShop* branded dispensary.

In Canada, Halo Collective acquired three KushBar retail cannabis stores located in Alberta as a first in its planned entry into the Canadian market, leveraging its Oregon and California brands. With the KushBar retail stores as a foundation, the company plans to expand its foothold in Canada.

Halo Collective has also acquired a range of software development assets, including CannPOS, Cannalift, and, more recently, CannaFeels. In addition, Halo Collective owns the discrete sublingual dosing technology, Accudab. The company intends to spin-off these assets and its intellectual property and patent applications into its subsidiary Halo Tek Inc. and expects to complete a distribution to shareholders on a record date to be determined by Halo Collective.

Halo Collective has recently announced its intention to reorganize its non-U.S. operations into a newly formed entity called Akanda Corp. (“Akanda“), whose mission will be to provide high-quality and ethically sourced medical cannabis products to patients worldwide. Akanda will seek to deliver on this promise while driving positive change in wellness, empowering individuals in Lesotho, and uplifting the quality of the lives of employees and the local communities where it operates, all while limiting its carbon footprint. Akanda will combine the scaled production capabilities of Bophelo Bioscience & Wellness Pty. Ltd., Halo Collective’s Lesotho-based cultivation and processing campus located in the world’s first Special Economic Zone (SEZ) containing a cannabis cultivation operation, with distribution and route-to-market efficiency of Canmart Ltd., Halo Collective’s UK-based fully approved pharmaceutical importer, and distributor that supplies pharmacies and clinics within the U.K. With a potential maximum licensed canopy area of 200 hectares (495 acres), Bophelo has scalability that is arguably unmatched in the world today.

For further information regarding Halo Collective, see Halo Collective’s disclosure documents on SEDAR at www.sedar.com.

Connect with Halo Collective: Email | Website | LinkedIn | Twitter | Instagram

About Red Light Holland Corp.

The company is an Ontario-based corporation positioning itself to engage in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal, recreational market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.

For additional information:

Todd Shapiro
Chief Executive Officer, Chairman, and Director
Tel: 647-204-7129
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements.

Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: statements regarding Red Light Oregon’s community outreach and advocacy programs; the intended outcomes and effects of Measure 109; statements regarding the implementation of Measure 109 by the Oregon Health Authority; Halo Collective’s expansion and vertical integration plans, including the buildout of Ukiah Ventures; Halo Collective’s intended spin-off of the assets, intellectual property, and patent applications of Accudab into its subsidiary Halo Tek Inc.; and Halo Collective’s plans to reorganize its non-U.S. operations into a newly formed entity called Akanda.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: Red Light Holland’s ability to continue as a going concern; the continued commercial viability and growth in popularity of psilocybin products; continued approval of Red Light Holland and Halo Collective’s activities by the relevant governmental and/or regulatory authorities; and the continued growth of Red Light Holland and Halo Collective.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of Red Light Holland to continue as a going concern; the risks associated with the psychedelics industry in general; increased competition in the recreational and medical psilocybin markets; the potential future unviability of the psychedelics industry; public opinion and perception of the psychedelics industry; incorrect assessment of the value and potential benefits of expansion plans and various transactions; risks associated with potential governmental and/or regulatory action with respect to the psychedelics industry; changes in general economic, business and political conditions, including changes in the financial and stock markets; and risks related to infectious diseases, including the impacts of the COVID-19 pandemic.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect Red Light Holland’s expectations as of the date hereof and are subject to change thereafter. Red Light Holland undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

September 28, 2021March 10, 2022

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD

Lobe Sciences Announces Data Demonstrating That Its Combination
Therapeutic Candidates are Significantly More Effective Than
Monotherapy in mTBI and PTSD

Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD

VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ – Lobe Sciences Ltd. (“Lobe” or the “Company“) (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical research studies, in established rodent models of mild traumatic brain injury/concussion (“mTBI”) and post-traumatic stress disorder (“PTSD”), using psilocybin plus N-Acetylcysteine (“NAC”). The study is being conducted in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the leadership of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

The rodents treated with the combination of psilocybin and NAC performed statistically significantly better (P < 0.000005) than the rodents treated with monotherapy with psilocybin, NAC or placebo.

Philip Young, CEO of Lobe stated, “I am thankful to Dr. Hoffer and his team for their excellent work. This data is validation of our therapeutic hypothesis that the use of these two active therapeutics provides superior efficacy to either placebo or single drug therapy in this model of TBI and PTSD. We believe that these data directly support our IP and will allow us to build on our leadership position in the rapidly evolving psychedelic therapeutics marketplace. Despite the significant shortage of psilocybin in North America the Miami team was able to deliver these data. However, the shortage has impacted the timing of the next planned studies. We have responded to this supply shortage by working to identify a manufacturing company who will supply high purity cGMP psilocybin to the University of Miami so that the remaining studies can be completed.”

Dr. Hoffer stated “These are promising results that suggest that a combination of psilocybin and NAC can work better than either drug administered as a single agent after traumatic brain injury. We look forward to future work that will help to reaffirm these outcomes and further clarify the role of medical countermeasures in combatting traumatic insults to the brain.”

Maghsoud Dariani, Chief Science Officer of Lobe said, “We are extremely pleased that the interim data from our preclinical studies validates our therapeutic hypothesis that NAC plus psilocybin would provide superior efficacy over either agent used alone. NAC remains the only compound that has successfully completed a human phase 1 equivalent trial in a population of individuals who had acute mTBI. Dr. Hoffer’s team has made significant in-roads studying psychedelic medicine and NAC specifically as it relates to mTBI and PTSD. Given there are currently no approved medicinal treatments for mTBI and PTSD, we feel this data is supportive of our plans to advance into future human clinical trials which we hope will eventually lead to approved therapeutics for these unmet needs.”

Trials Methodology And Results

Rodent models have been essential for revealing the normal and pathological processes that influence learning and memory. The University of Miami team has extensive experience and expertise in running these and other important models. In a standard model of normal behavior that assess the amount of time that rodents exhibit exploratory activity, rodents who underwent trauma and treated with the combination agents spent significantly more time exploring than they did with single agents or vehicle alone. The rodents treated with the combination of psilocybin and NAC performed statistically significantly better (P < 0.000005) than the rodents treated with monotherapy with psilocybin, NAC or placebo.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE NOT REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company; the development of effective delivery methods and commercialization potential of the nasal mist device; research and development using NAC and psilocybin and growth of the business; the timing of and results from the University of Miami pre-clinical study; the ability to access a supply high purity cGMP psilocybin for the Company’s studies; anticipated timing and announcement of initiation of the first human study with Lobe’s patent pending combination therapeutics of psilocybin and NAC (N-Acetylcysteine); statements and expected timing regarding cGMP psilocybin supply and availability; expected advancement into future human clinical trials; statements regarding future approved therapeutics; and the expected timing for the launch of new products and revenue-generating activities, are all forward looking statements that involve risks and uncertainties. Forward-looking statements, by their very nature, require management to make assumptions and are subject to inherent risks and uncertainties, and while management of the Company believes the forward-looking statements contained herein have a reasonable basis, the possibility exists that our predictions, forecasts, projections, expectations or conclusions will not prove to be accurate. Material assumptions that underlie the forward-looking statements included in this news release include, without limitation, assumptions regarding: the outcomes of scientific studies showing the efficacy of psychedelic therapies on mTBI and PTSD, increasing acceptance in the medical community and among consumers for psychedelic therapies as an effective treatment modality; the Company having access to sufficient capital needed to support its various objectives, expected synergies from M&A transactions and the timing of future studies, regulatory approvals and our ability to capitalize on business opportunities; the Company having availability and supply of high-purity cGMP psilocybin; and the impact of COVID-19 on our business plans. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. As a result of the inherent uncertainty of forward-looking statements, there can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements, whether as a result of known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. Important risks and uncertainties that could cause actual results to differ materially from the Company’s expectations include without limitation risks relating to: that we may not have the capital needed or will not be able to raise sufficient capital to support our business activities or achieve our anticipated milestones; delays or stoppages in the Company’s business activities resulting from the COVID-19 pandemic; adverse or unexpected findings in scientific research; adverse changes to the regulatory environment in which we operate; regulatory delays or the failure to obtain required regulatory approvals; failure to capitalize on business opportunities and develop revenue-generating activities; contract counterparty risks; key personnel risk; business integration risks; risks inherent to equity and debt markets and their effects on our share price, and such other risks as may be detailed from time to time in the filings made by the Company pursuant to securities regulations, as well as other risks that may presently be unknown to us or which we consider to be immaterial at the time such forward-looking statements are made. As a result of these risks and uncertainties, the Company cannot guarantee that any forward-looking statement will materialize as expected, and the reader is therefore cautioned not to place undue reliance on any forward-looking statements contained in this news release. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement, are made only as of the date of this news release and the Company does not intend to update any of the forward-looking statements contained in this news release except as expressly required by applicable securities laws.

SOURCE Lobe Sciences Ltd.

September 28, 2021March 10, 2022

Lamar Odom To Speak At Meet Delic In Las Vegas

NBA superstar to speak at Meet Delic in Las Vegas about his embrace of psychedelic treatments and screen the film which chronicles his near-fatal overdose and recovery with psychedelics. He joins world’s leading experts, scientists, and health & wellness advocates to gather for a two-day immersive edutainment experience at AREA15 from November 6 – 7, 2021.

Vancouver, BC, September 28, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on November 7. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers, earning him NBA championships in 2009 and 2010. He joined LeBron James, Allen Iverson, Tim Duncan and Dwayne Wade as members of the goldwinning U.S. men’s basketball team at the 2004 Athens Olympics.

In 2015 Odom was hospitalized in Las Vegas after a near-death overdose that resulted in multiple seizures, strokes and a coma. The upcoming documentary Lamar Odom Reborn chronicles his life, from past traumas and struggles with anxiety and substance abuse to his recovery and healing through psychedelic treatments, meditation and breathwork. Odom’s keynote “Fireside Chat: Lamar Odom & Zappy Zapolin: Reborn” will reunite him with the documentary’s director for an intimate discussion of his healing journey with psychedelic medicine and a preview of the film.

“We’re so honored Lamar will be sharing his personal story of healing with all of us at Meet Delic,” said Jackee Stang, co-founder of Delic. “He has shown tremendous courage facing his past traumas and addiction, and his openness to exploring psychedelic treatments is inspiring. We hope his story will open the hearts and minds of more people so we can truly address the growing mental health crisis we’re facing.”

The twenty hours of panels and keynotes will include an array of topics such as “Why Are Psychedelics Medicine?”, “How Big Money is (Already) Playing Psychedelics,” “PTSD Reset and Recovery,” “Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World,” “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” “Microdosing,” “Psychedelic Activism,” “Aphrodisiacs and Psychedelics: A History of Medicine for Love”, “How Psychedelics Can be Effectively Used for Physical Optimization,” and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

About Meet Delic

About Delic Corp

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forwardlooking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forwardlooking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, mjaramillo@labeltheagency.com

September 28, 2021March 10, 2022

NeonMind Advances Strategy For Specialty Clinic Launch

Company expects to launch first specialty clinic locations by early 2022

NeonMind-branded specialty mental health clinics to bring innovative interventional psychiatry treatments to underserved populations in Canada

Vancouver, B.C. – September 28, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company, today provided an update on the Company’s medical services division, including its specialty clinics initiative to establish a national network of clinics offering interventional psychiatry treatments. The Company recently established a best-in-class Specialty Clinics Advisory Board to oversee the advancement of its medical services division and is currently in advanced negotiations with potential partners to launch locations in early 2022.

Specialty Mental Health Clinics Update

To continue its commitment in providing access to psychedelic-based treatments for mental health disorders, NeonMind is working to establish NeonMind-branded specialty mental health clinics. The Company is in ongoing discussions with a number of key opinion leaders and potential strategic partners, all of which are progressing successfully and are currently in late-stage assessments.

Based on the progress to-date, NeonMind expects its first clinic to go live by early 2022. Following the first clinic opening, the Company anticipates the launch of additional clinic locations throughout the course of 2022, continuing to expand locations and services in 2023 and beyond.

“We continue to be encouraged by the clinical promise and market potential for interventional psychiatry,” said Rob Tessarolo, President and CEO of NeonMind. “There is unprecedented demand for these innovative treatments and we have an opportunity to be the first major player in this space. We continue to have late stage discussions as we evaluate a series of potential opportunities and partnerships, which we believe will be transformational for NeonMind and the patients we aim to serve.”

Mr. Tessarolo added, “Our discussions are focused on operational partners with a proven track record of success in the medical treatment space to operate our national clinic network in a capital efficient manner. We are encouraged by the reception we have received and look forward to providing further updates as these discussions continue to advance.”

Strategic Opportunity in Interventional Psychiatry – Addressing a Major Medical Market

Mental health disorders have reached a crisis level, which has been compounded by the effects of the COVID-19 pandemic, in particular, depression and anxiety disorders. The economic burden is massive with an estimated cost of $51 billion annually to Canadians¹. Traditional treatments such as pharmacotherapy and psychotherapy have varying degrees of effectiveness, but for the most part leave the crisis largely unaddressed.

A new and promising field of interventional psychiatry including ketamine/esketamine, neurostimulation, and psychedelic treatment modalities are showing unprecedented clinical efficacy. This new modality is establishing itself as a game changing and staple armamentarium for patients and clinicians. Despite this, broader access to these treatments remains extremely limited in Canada due to a lack of infrastructure and awareness.

Importantly, these treatments require specialized clinic models and treatment teams which is the focus of NeonMind’s medical services division: to establish NeonMind-branded, best-in-class, national specialty clinics network providing interventional psychiatry treatments tailored for local communities’ healthcare needs.

Strategically, NeonMind’s near-term focus is to scale its services to address the large demand for clinician-validated treatments including ketamine/esketamine and neurostimulation. With impending regulatory approvals for psychedelic modalities including MDMA for anxiety disorders, psilocybin for depression disorders and NeonMind’s proprietary psychedelic treatment for weight management, NeonMind’s clinics will also adopt these treatments and serve as future access points to psychedelic modalities, providing important strategic exposure to the psychedelics market.

World-Class Specialty Clinics Advisory Board to Guide Build-Out of National Clinic Network

To support a best-in-class integrated services platform and comprehensive set of programs, NeonMind has successfully built an industry-leading advisory board of top-rated clinicians, including Dr. Sagar Parikh, MD, Dr. Roumen Milev, MD/PhD, and Dr. Gustavo Vazquez, MD/PhD. These board members bring practical and scientific accolades in depression and anxiety disorders and interventional psychiatry which will help further our mission.

All three advisors are highly renowned and considered to be at the forefront of this transformational field with academic influence and significant involvement in national societies and initiatives such as the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the Canadian Biomarker Integration Network for Depression (CAN-BIND). Moreover, they offer vast clinical and research experience from Canada, US and Latin America with hands-on success in setting up and managing interventional psychiatry practices that integrate psychedelics such as ketamine and esketamine. Combined, they have effectively provided thousands of interventional psychiatry treatments to patients.

¹ Overall Economic Burden of Mental Health, www.camh.ca/en/driving-change/the-crisis-is-real/mental-health-statistics

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. For more information on NeonMind, go to www.NeonMindBiosciences.com

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

Investor Relations:

KCSA Strategic Communications

Scott Eckstein/Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

Media Inquiries:

KCSA Strategic Communications
Annie Graf

neonmind@kcsa.com

Tel: 786-390-2644

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

September 27, 2021March 10, 2022

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

Funding to Open New Psychedelic Wellness Clinic Locations, Adding to Leading Footprint

Not for dissemination in the United States or to U.S. newswire services

VANCOUVER, BC September 27, 2021 – Delic Holdings Corp. (“Delic” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) is pleased to announce that it has closed its previously announced sale to a single institutional investor for gross proceeds of approximately C$7.0 million in a private placement in the United States (the “Private Placement“).

Pursuant to the Private Placement, the Company issued ‎9,000,000 units of the Company (the “Units“) at a price of C$0.285 per Unit and 15,561,404 pre-funded ‎units of the Company (the “Pre-Funded Units“) at a price of C$0.2849. Each Unit is comprised of one subordinate voting share (a “SV Share“) and one subordinate voting share purchase warrant (a “Warrant“). Each Warrant entitles the holder thereof to purchase one ‎additional SV Share (a “Warrant Share“) at an exercise price of C$0.38 per Warrant Share, subject to ‎‎adjustment, at any time on or prior to 5:00 p.m. ‎‎(Eastern Time) on September 28, 2026. Each Pre-Funded Unit is comprised of one pre-funded subordinate voting share purchase warrant ‎‎(a “Pre-Funded Warrant“) and one Warrant. Each ‎Pre-Funded Warrant entitles the holder thereof to purchase one SV Share (a “Pre-Funded Warrant Share“) at ‎an exercise price of C$0.0001 per Pre-Funded Warrant Share and shall terminate upon exercise in full of ‎the Pre-Funded Warrants. ‎‎

H.C. Wainwright & Co. (“H.C. Wainwright“) acted as the exclusive placement agent for the Private Placement.

H.C. Wainwright received (i) a cash commission of $560,000.01 (equal to 8.0% of the gross proceeds of the Private Placement) and (ii) 1,964,912 compensation warrants (the “Agent Warrants“). Each Agent Warrant entitles the holder thereof to purchase one SV Share at an exercise price of C$0.38 per SV Share at any time on or prior to 5:00 pm (Eastern Time) on September 28, 2026.

The SV Shares, Pre-Funded Warrants and Warrants issued under the Private Placement were qualified by way of a prospectus supplement dated September 24, 2021 under the Company’s short form base shelf prospectus dated September 14, 2021 (the “Prospectus Supplement“) which was filed in the Province of British Columbia. In the United States, the SV Shares, Pre-Funded Warrants and Warrants and the shares issuable upon the exercise of the Pre-Funded Warrants and Warrants were offered on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), and certain other jurisdictions in accordance with applicable securities laws.

The Company intends to use the net proceeds of the Private Placement for expanding clinic foot print, operating costs and acquisitions.

The Private Placement is subject to customary notices and deliveries to the Canadian Securities Exchange.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in Canada in connection with the Private Placement.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities being offered have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of U.S. Persons (within the meaning of Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Delic Corp, Inc.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: use of the net proceeds of the Private Placement; and the receipt of all necessary regulatory and stock exchange approvals for the Private Placement.

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

the potential impact of the closing of the Private Placement on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; and compliance ‎with extensive government regulation.

Media Relations Contact

Rich Rodriguez

rich@deliccorp.com

Investor Relations Contact

Daniel Southan-Dwyer

dsd@deliccorp.com

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Category: Silo Wellness

Delic Labs Applies for Dealers License to Commercialize Psychedelics Research, Health Exemption to Test MDMA and LSD

Delic Labs Applies for Dealers License to Commercialize Psychedelics Research, Health Exemption to Test MDMA and LSD

Dr. Molly Maloof, Physician, Technologist and Entrepreneur, To Keynote At Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Dr. Molly Maloof, Physician, Technologist and Entrepreneur, To Keynote At Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application

Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application

Company utilizes green chemistry to stabilize natural product with higher yields

Wesana Health Announces Inclusion in the AdvisorShares Psychedelics ETF

Wesana Health Announces Inclusion in the AdvisorShares Psychedelics ETF

Delic Partnership With Paradigm Healthcare Of Georgia Brings Clinically Relevant Toxicology Testing To Ketamine Treatment For First Time

Delic Partnership With Paradigm Healthcare Of Georgia Brings Clinically Relevant Toxicology Testing To Ketamine Treatment For First Time

About Ketamine Infusion Centers

Red Light Holland: Initial Results From Red Light Oregon Market Research in Oregon Show 86% of Adults Interested in Psilocybin Services are Interested in Microdosing

Red Light Holland: Initial Results From Red Light Oregon Market Research in Oregon Show 86% of Adults Interested in Psilocybin Services are Interested in Microdosing

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD

Lamar Odom To Speak At Meet Delic In Las Vegas

Lamar Odom To Speak At Meet Delic In Las Vegas

About Meet Delic

About Delic Corp

Forward-Looking Information and Statements

NeonMind Advances Strategy For Specialty Clinic Launch

NeonMind Advances Strategy For Specialty Clinic Launch

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

DailyMushroom

© 2024 DAILY MUSHROOM. All Rights Reserved